Your browser is no longer supported. Please, upgrade your browser.
Settings
AXSM [NASD]
Axsome Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.67 Insider Own21.47% Shs Outstand37.43M Perf Week-9.48%
Market Cap1.90B Forward P/E- EPS next Y-2.35 Insider Trans0.01% Shs Float29.50M Perf Month-27.97%
Income-99.70M PEG- EPS next Q-0.97 Inst Own62.80% Short Float9.21% Perf Quarter-19.63%
Sales- P/S- EPS this Y-37.70% Inst Trans-0.32% Short Ratio7.57 Perf Half Y-28.64%
Book/sh2.57 P/B18.91 EPS next Y38.20% ROA-53.30% Target Price- Perf Year-34.87%
Cash/sh4.21 P/C11.54 EPS next 5Y- ROE-79.80% 52W Range50.05 - 90.00 Perf YTD-40.36%
Dividend- P/FCF- EPS past 5Y-22.00% ROI- 52W High-46.01% Beta2.54
Dividend %- Quick Ratio7.60 Sales past 5Y- Gross Margin- 52W Low-2.92% ATR2.84
Employees60 Current Ratio7.60 Sales Q/Q- Oper. Margin- RSI (14)27.25 Volatility5.48% 5.04%
OptionableYes Debt/Eq0.00 EPS Q/Q10.80% Profit Margin- Rel Volume1.36 Prev Close50.57
ShortableYes LT Debt/Eq0.50 EarningsAug 09 BMO Payout- Avg Volume358.83K Price48.59
Recom1.70 SMA20-17.35% SMA50-21.68% SMA200-27.73% Volume487,648 Change-3.92%
Jun-10-21Initiated Berenberg Buy $112
Jan-08-21Initiated Jefferies Buy $129
Dec-16-20Initiated Mizuho Buy $120
Sep-29-20Initiated BofA Securities Underperform $66
Sep-10-20Initiated Morgan Stanley Overweight $102
Apr-28-20Reiterated H.C. Wainwright Buy $200 → $210
Apr-14-20Initiated Cowen Outperform $95
Dec-30-19Reiterated H.C. Wainwright Buy $170 → $200
Dec-17-19Reiterated H.C. Wainwright Buy $30 → $170
Dec-16-19Reiterated Guggenheim Buy $65 → $158
Oct-16-19Initiated Guggenheim Buy $48
Sep-18-19Initiated William Blair Outperform
May-28-19Initiated SunTrust Buy
May-23-19Reiterated H.C. Wainwright Buy $23 → $30
Apr-08-19Initiated SVB Leerink Outperform $25
Mar-15-19Reiterated H.C. Wainwright Buy $15 → $18
Oct-03-16Resumed Brean Capital Buy
Dec-15-15Initiated Cantor Fitzgerald Buy
Dec-14-15Initiated Ladenburg Thalmann Buy
Jul-30-21 06:21AM  
Jul-28-21 07:41PM  
Jul-26-21 09:19PM  
11:50AM  
Jul-22-21 08:00AM  
Jul-19-21 04:30PM  
Jul-18-21 10:40AM  
Jul-15-21 08:17PM  
11:00AM  
07:00AM  
Jul-14-21 10:08PM  
04:32PM  
09:12AM  
Jun-28-21 01:29AM  
Jun-23-21 05:52AM  
Jun-16-21 08:00AM  
Jun-15-21 09:34AM  
07:00AM  
Jun-09-21 11:30AM  
Jun-05-21 06:31AM  
May-11-21 11:21AM  
May-10-21 05:30PM  
07:00AM  
06:15AM  
May-07-21 08:44AM  
07:00AM  
Apr-30-21 06:25AM  
Apr-28-21 06:20AM  
Apr-27-21 07:00AM  
Apr-26-21 12:16PM  
12:00PM  
07:54AM  
06:00AM  
Apr-24-21 11:00AM  
Apr-22-21 12:05PM  
09:15AM  
Mar-31-21 11:30AM  
Mar-30-21 02:05AM  
Mar-11-21 10:06AM  
Mar-02-21 09:40AM  
Mar-01-21 06:30PM  
07:00AM  
06:30AM  
Feb-19-21 07:00AM  
Feb-16-21 07:00AM  
Feb-10-21 06:00AM  
Jan-27-21 07:05AM  
Jan-07-21 08:48AM  
Jan-04-21 09:30AM  
Dec-31-20 06:15AM  
06:00AM  
Dec-30-20 12:25AM  
Dec-17-20 05:25PM  
Dec-08-20 06:00AM  
Dec-05-20 11:31AM  
Dec-02-20 06:00AM  
Dec-01-20 06:00AM  
Nov-06-20 11:31PM  
11:30AM  
Nov-05-20 07:00AM  
06:15AM  
Nov-04-20 07:03AM  
07:03AM  
Nov-03-20 07:00AM  
Oct-28-20 07:00AM  
Oct-01-20 11:14AM  
Sep-29-20 12:00PM  
07:00AM  
Sep-24-20 06:00AM  
Sep-22-20 12:19PM  
Sep-21-20 07:00AM  
Sep-17-20 07:00AM  
Sep-15-20 12:46AM  
Sep-14-20 06:00AM  
Sep-10-20 07:00AM  
Sep-09-20 11:30AM  
Sep-08-20 07:00AM  
Sep-03-20 07:00AM  
Aug-31-20 07:00AM  
Aug-28-20 07:00AM  
Aug-20-20 07:00AM  
Aug-11-20 01:05PM  
Aug-10-20 04:44PM  
07:05AM  
07:00AM  
Aug-05-20 07:00AM  
Jul-30-20 07:00AM  
Jul-25-20 07:10AM  
Jul-16-20 12:21PM  
Jul-15-20 01:15PM  
12:05PM  
Jul-14-20 12:16PM  
Jul-13-20 07:00AM  
Jul-08-20 02:41PM  
Jul-07-20 11:14AM  
Jul-03-20 03:19PM  
Jun-29-20 12:49PM  
Jun-26-20 07:00AM  
Jun-15-20 12:24PM  
Jun-07-20 11:30AM  
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05 for the treatment major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial for the treatment of Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. The company is also developing AXS-07 for the treatment of migraine; AXS-12 for the treatment of narcolepsy; and AXS-14 for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Coleman MarkDirectorMay 12Buy58.1550029,075420,998May 13 07:05 AM